| scholarly article | Q13442814 |
| P2093 | author name string | W E Miller | |
| N Raab-Traub | |||
| K L Fries | |||
| P2860 | cites work | A novel RING finger protein interacts with the cytoplasmic domain of CD40 | Q24306382 |
| Involvement of CRAF1, a relative of TRAF, in CD40 signaling | Q24306746 | ||
| bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death | Q24312157 | ||
| Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death | Q24312211 | ||
| A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor | Q24318280 | ||
| The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases | Q24319848 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation | Q28249159 | ||
| Mutations in the p53 gene occur in diverse human tumour types | Q28249770 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin | Q28299110 | ||
| p53 mutations in human cancers | Q28302973 | ||
| The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family | Q28307399 | ||
| TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 | Q28610812 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease | Q43936463 | ||
| p53 mutation in human nasopharyngeal carcinomas | Q44195191 | ||
| Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals | Q44953164 | ||
| Epstein-Barr virus gene expression in nasopharyngeal carcinoma | Q45205828 | ||
| Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation | Q45800684 | ||
| DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative | Q45803144 | ||
| The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. | Q45835618 | ||
| Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. | Q45841044 | ||
| Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases | Q45845223 | ||
| The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B | Q45876441 | ||
| The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines | Q45878333 | ||
| Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. | Q53505779 | ||
| An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. | Q53541156 | ||
| Thymocyte apoptosis induced by p53-dependent and independent pathways. | Q54242475 | ||
| Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx | Q56689988 | ||
| Wild-type p53 activates transcription in vitro | Q59054260 | ||
| A20 zinc finger protein inhibits TNF and IL-1 signaling | Q59487872 | ||
| The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia | Q62746091 | ||
| p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features | Q67841746 | ||
| The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest | Q71761308 | ||
| Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways | Q72831542 | ||
| Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53 | Q72871721 | ||
| Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control | Q29616465 | ||
| mdm2 expression is induced by wild type p53 activity | Q29618316 | ||
| Participation of p53 protein in the cellular response to DNA damage | Q29618319 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 | Q29622924 | ||
| Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity | Q30452167 | ||
| EBV gene expression in an NPC-related tumour. | Q33576708 | ||
| Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells | Q33929593 | ||
| Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma | Q33937673 | ||
| The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein | Q33938629 | ||
| Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein | Q34343950 | ||
| The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. | Q34561178 | ||
| Two TNF receptors | Q35231014 | ||
| Structural analyses of the Epstein-Barr virus BamHI A transcripts | Q35832657 | ||
| The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. | Q35841701 | ||
| Apoptosis and programmed cell death in immunity | Q36135180 | ||
| Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation | Q36575274 | ||
| Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. | Q36628203 | ||
| Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. | Q36697762 | ||
| Alterations of the p53 gene in nasopharyngeal carcinoma | Q36698270 | ||
| Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 | Q36806063 | ||
| Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo | Q36822172 | ||
| Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. | Q37013182 | ||
| Wild-type p53 is a cell cycle checkpoint determinant following irradiation | Q37152060 | ||
| Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda | Q38892203 | ||
| Nasopharyngeal carcinoma. X. Presence of Epstein-Barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya | Q38970951 | ||
| Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins | Q39870850 | ||
| All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. | Q40044497 | ||
| DNA damage, oncogenesis and the p53 tumour-suppressor gene | Q40389197 | ||
| Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53 | Q40806210 | ||
| p53 is frequently mutated in Burkitt's lymphoma cell lines | Q41082472 | ||
| Expression of epstein-barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients | Q41154554 | ||
| Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis | Q41343773 | ||
| Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers | Q41447311 | ||
| Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. | Q41508377 | ||
| Biological activities of p53 mutants in Burkitt's lymphoma cells | Q41555135 | ||
| Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. | Q41563742 | ||
| Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis | Q41563751 | ||
| Absence of p53 gene mutations in primary nasopharyngeal carcinomas | Q41604318 | ||
| Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene | Q41661999 | ||
| Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death | Q41678654 | ||
| Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells | Q41807177 | ||
| Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus | Q41976287 | ||
| Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma | Q42507253 | ||
| SV40 T antigen abrogates p53-mediated transcriptional activity. | Q42805922 | ||
| Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| membrane protein | Q423042 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 8653-8659 | |
| P577 | publication date | 1996-12-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene | |
| P478 | volume | 70 |
| Q39736828 | A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. |
| Q39246185 | A systematic screen reveals MicroRNA clusters that significantly regulate four major signaling pathways |
| Q45709688 | Absence of p53 alterations in nasopharyngeal carcinoma Spanish patients with Epstein-Barr virus infection |
| Q37583544 | Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells |
| Q35488742 | Adenovirus replaces mitotic checkpoint controls |
| Q37123246 | Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation |
| Q39551815 | CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus. |
| Q39176686 | Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines |
| Q33813615 | Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. |
| Q38097263 | Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies |
| Q42370582 | Downregulation of A20 increases the cytotoxicity of IFN-γ in hepatocellular carcinoma cells |
| Q30979226 | Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes |
| Q37596895 | EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. |
| Q36772369 | EBV and not HPV sensitizes tobacco-associated head and neck cancer cell line FaDu to radiotherapy |
| Q35040644 | EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management |
| Q26775442 | Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments |
| Q33843334 | Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation |
| Q34154616 | Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis |
| Q39595269 | Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta |
| Q36559750 | Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation |
| Q41570251 | Epstein-Barr virus infection is inversely correlated with the expression of retinoblastoma protein in Reed-Sternberg cells in classic Hodgkin lymphoma |
| Q40155828 | Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas |
| Q28082701 | Epstein-Barr virus latent genes |
| Q35024009 | Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway |
| Q34872837 | Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities |
| Q33641167 | Epstein-Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression |
| Q39451096 | Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins |
| Q24516975 | Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2 |
| Q39444685 | Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma |
| Q36327458 | Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice |
| Q39852028 | Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification |
| Q33809963 | Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections |
| Q24299740 | IRF7: activation, regulation, modification and function |
| Q37596540 | Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. |
| Q40487971 | Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation |
| Q39875400 | Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds. |
| Q33786551 | Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression |
| Q24646670 | Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes |
| Q37596432 | Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties |
| Q33792860 | Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1 |
| Q33834888 | Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. |
| Q33724843 | Interleukins, laminin and epstein - barr virus latent membrane protein 1 (EBV LMP1) Promote metastatic phenotype in nasopharyngeal carcinoma |
| Q33870488 | Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7. |
| Q35533486 | Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis |
| Q49787520 | LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death |
| Q39589020 | LMP1 of Epstein-Barr virus induces proliferation of primary mouse embryonic fibroblasts and cooperatively transforms the cells with a p16-insensitive CDK4 oncogene |
| Q39895212 | MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival |
| Q36747951 | Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis |
| Q40335673 | NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo |
| Q36961875 | Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. |
| Q41662260 | Nuclear factor κB represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells |
| Q26830643 | Oncogenes and RNA splicing of human tumor viruses |
| Q43156756 | Oncogenic activity of Epstein-Barr virus latent membrane protein 1 (LMP-1) is down-regulated by lytic LMP-1. |
| Q39683197 | Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas |
| Q35861281 | Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells. |
| Q24552501 | Repression of RNA polymerase I transcription by the tumor suppressor p53 |
| Q43010429 | Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas |
| Q37693272 | STAT1 and pathogens, not a friendly relationship |
| Q38359234 | TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. |
| Q24306662 | The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7 |
| Q34350684 | The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms |
| Q38728203 | The Linear Ubiquitin Assembly Complex Modulates Latent Membrane Protein 1 Activation of NF-κB and Interferon Regulatory Factor 7. |
| Q39592173 | The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line |
| Q50064513 | The interactome of EBV LMP1 evaluated by proximity-based BioID approach |
| Q91996237 | The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies |
| Q38264787 | The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma |
| Q24674848 | The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2 |
| Q38540498 | The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes |
| Q33791751 | The role of viral and bacterial pathogens in gastrointestinal cancer. |
| Q24685892 | The viral etiology of AIDS-associated malignancies |
| Q27016002 | Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma |
| Q39787510 | Transcriptional downregulation of p27KIP1 through regulation of E2F function during LMP1-mediated transformation. |
| Q39577216 | Transforming potential of the herpesvirus oncoprotein MEQ: morphological transformation, serum-independent growth, and inhibition of apoptosis. |
| Q38631755 | Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1. |
| Q37810431 | Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention |
| Q26823898 | Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients |
| Q35067738 | Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. |
| Q89597918 | Viral miRNAs as Active Players and Participants in Tumorigenesis |
| Q34394771 | Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses |
| Q34308884 | Viruses and apoptosis |
| Q24530708 | Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity |
| Q33785919 | p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection |
| Q33814900 | p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication |
Search more.